Background/Aims

Asthma is characterized by chronic inflammation. Inhaled corticosteroids (ICS) remain the cornerstone of anti-inflammatory therapy, targeting both the large and small airways.

Methods

This randomized open-label crossover trial included 30 patients receiving step 3 inhaled medication according to the Global Initiative for Asthma (GINA). Patients received beclomethasone/formoterol (BDP/F) for maintenance and reliever therapy for 6 weeks, followed by budesonide/formoterol (BUD/F) for 6 weeks, or vice versa, with a 4-week washout period in between. Assessments at each visit included the Asthma Control Test (ACT), Asthma Control Questionnaire, Quality of Life Questionnaire for Adult Korean Asthmatics, and pulmonary function test. The primary endpoint was the change in forced expiratory flow between 25% and 75% of vital capacity (FEF_25–75% pred).

Results

Twenty-four patients (15 females, mean age 39.3 years) completed the study. The changes in FEF_25–75% pred were comparable between BDP/F and BUD/F (5.79 ± 38.34 vs. −1.36 ± 14.93, p = 0.399). No significant differences were observed between the BDP/F and BUD/F groups in terms of improvement in asthma control or quality of life. However, in the subgroup of patients with positive methacholine bronchial provocation tests, BDP/F significantly improved ACT scores compared to BUD/F (0.92 ± 2.25 vs. −1.31 ± 3.04, p = 0.044).

Conclusions

Our study demonstrated that extrafine ICS treatment provided no significant advantage over non-extrafine ICS in improving small airway obstruction or overall asthma control in moderate asthma. This suggests that factors other than particle size may contribute to treatment outcomes.

Key words: Asthma; Beclomethasone; Budesonide; Forced expiratory flow between 25% and 75% of vital capacity; Treatment outcome

Graphical abstract

INTRODUCTION

Asthma is a chronic inflammatory respiratory condition characterized by episodic airway obstruction and increased bronchial responsiveness, leading to symptoms such as wheezing, shortness of breath, chest tightness and cough [1]. Suppressing chronic airway inflammation is increasingly being recognized as a critical component of asthma management. Consequently, anti-inflammatory maintenance therapy remains the cornerstone of asthma treatment in contemporary practice [2,3]. Among anti-inflammatory medications, inhaled corticosteroids (ICS) are regarded as the most effective option, demonstrating safety at appropriate doses for long-term use in both children and adults with asthma. Additionally, ICS can be combined with long-acting inhaled β2-agonist (LABA) to achieve effective asthma control in patients whose symptoms are not adequately managed with ICS alone [4,5]. Small airways, defined as those with an internal diameter of less than 2 mm, occur in all stages of asthma and contribute significantly to its pathophysiology [6]. Asthma-related airway inflammation involves both the large and small airways. Therefore, enhancing total lung deposition, with a focus on targeting both large and small airways, may amplify the anti-inflammatory effects of ICS and potentially improve asthma outcomes [7,8]. ICS formulations differ in particle size owing to variations in their composition and propellants. For effective deposition in the lower respiratory tract beyond the carina, particles must be less than 5 μm in diameter. Specifically, particles smaller than 2 μm, referred to as the “extrafine particle fraction,” are considered the most effective for deposition in small airways [9].

A previous study comparing two pressurized metered-dose inhalers (pMDIs) found that using pMDIs with extrafine particles (beclomethasone/formoterol, BDP/F) may better alleviate small airway obstruction than non-extrafine particle inhalers (budesonide/formoterol, BUD/F), despite no significant differences in overall treatment outcomes [10]. According to the Global Initiative for Asthma (GINA) guidelines, ICS and formoterol combinations (BDP/F and BUD/F) are the preferred treatments for symptom relief in mild asthma (Steps 1 and 2) and for daily maintenance and reliever therapy (MART) in moderate to severe asthma (Steps 3, 4, and 5) [11]. Furthermore, studies have demonstrated that dry powder inhalers (DPIs) are as effective as pMDIs in delivering ICS and formoterol combinations [12,13]. In this study, we conducted a comprehensive evaluation of the clinical benefits of extra-fine particle ICS delivered via DPI in combination with MART, focusing on symptom control and improvements in both small and large airway functions—an area that has not yet been thoroughly investigated.

METHODS

Study design

Study design

This was a 20-week, single-center, randomized, open-label crossover trial. At enrollment and during each visit, patients were educated on proper inhaler use. During the study period, including the run-in and washout phases, all patients used an inhaled corticosteroid (fluticasone propionate 250 μg) twice daily along with a short-acting β2-agonist (salbutamol 100 μg) as a reliever. After a 4-week run-in period, patients were randomized into two groups using an Excel program (Microsoft, Redmond, WA, USA) with a block size of 10. Subsequently, they were assigned in a crossover design to receive open-label treatment with either BDP/F (beclomethasone dipropionate 100 μg/formoterol fumarate dihydrate 6 μg, extra-fine particles) or BUD/F (budesonide 160 μg/formoterol fumarate dihydrate 4.5 μg) for 6 weeks. Patients received one inhalation of either BDP/F or BUD/F twice daily as maintenance therapy (two inhalations per day) and one inhalation as needed for symptom relief. Total daily inhalations were limited to a maximum of eight per day, and the same criteria were applied to both inhalers based on the findings of a study involving Korean asthmatic patients (Fig. 1) [14].

Enrollment

Enrollment

Patients attending the outpatient clinic were enrolled if they met the following inclusion criteria: (1) aged 19 years or older; (2) exhibited typical asthma symptoms such as wheezing, shortness of breath, chest tightness, or coughing, exacerbated by triggers including exercise, colds, changes in climate or diurnal temperature, allergens, air pollution, tobacco smoke, or strong odors; (3) demonstrated a bronchodilator response (BDR) or treatment response through repeated lung function tests (defined as a ≥ 200 mL and ≥ 12% increase in forced expiratory volume in 1 second [FEV₁] from baseline after salbutamol inhalation or appropriate asthma treatment) or airway hyperresponsiveness (AHR) confirmed by a methacholine challenge test (provocative concentration of methacholine causing a 20% drop in FEV₁ [PC20] ≤ 16 mg/mL); (4) were on initial asthma treatment as defined by GINA guidelines, specifically low-dose ICS/LABA (Step 3); and (5) demonstrated the ability to be trained in the correct use of a DPI device.

Outcome measurements

Outcome measurements

Various indicators are available for assessing small airway obstruction. The primary outcome of this study was the effect on small airway obstruction, assessed by the percentage of predicted values for forced expiratory flow between 25% and 75% of vital capacity (FEF_25–75% pred), comparing extrafine and non-extrafine ICS treatments. This study aimed to validate previous findings by comparing the effects of extrafine particle transition from pMDI to DPI formulations [10].

Secondary outcomes included changes in asthma control and asthma-specific quality of life (Asthma Control Test [ACT], Asthma Control Questionnaire [ACQ], Quality of Life Questionnaire for Adult Korean Asthmatics [QLQAKA]) and lung function tests. Local and systemic adverse events (AEs) were recorded after each 6-week treatment period.

Statistical analysis

Statistical analysis

This study explored the effects of particle size differences in inhaler therapy in patients with asthma. Based on previous inhaler studies, sample size calculation was performed using the mean difference (62.58%) and standard deviation (SD) (94.80%) of FEF_25–75% pred, a marker of small airway obstruction [10]. Using a two-sided test with α = 0.05 and β = 0.2, the required sample size was 24.112. Accounting for a 20% dropout rate, the final number of patients was determined to be 30. Continuous variables between groups were compared using the Student’s t-test, and categorical variables were analyzed using the chi-square test or Fisher’s exact test. Data are expressed as mean ± SD for continuous variables and as frequencies (%) for categorical variables. Intervisit differences between groups were analyzed using a paired t-test. Unadjusted changes in lung function and symptom control status in each treatment group were analyzed using a Linear Mixed Model. Statistical significance was set at p < 0.05. All analyses were performed using R version 4.4.0 (R Foundation for Statistical Computing, Vienna, Austria).

Ethical consideration

Ethical consideration

The study protocol was reviewed and approved by the Institutional Review Board of Gachon University Gil Medical Center (approval number: GCIRB2021-222). This study was registered in the Clinical Research Information Service of the Republic of Korea (CRIS KCT0006933). All participants were enrolled after obtaining their informed consent.

RESULTS

Baseline characteristics

Baseline characteristics

Of the 30 enrolled patients, 24 (12 in group A [BDP/F followed by BUD/F], and 12 in group B [BUD/F followed by BDP/F]) completed the study. This discrepancy was due to withdrawal (n = 2) and loss to follow-up (n = 4) (Fig. 2). The mean age of the enrolled patients was 39.3 ± 15.2 years, and 62.5% were female. The mean body mass index (BMI) was 27.6 kg/m², and 20.8% of the patients were classified as obese (BMI ≥ 30.0 kg/m²). The mean duration of asthma symptoms was 16 months and the mean frequency of exacerbations in the past year was 2.8 ± 1.7. The baseline scores for ACT, ACQ, and QLQAKA were 15.9, 2.0, and 3.4, respectively. Approximately 80% of the patients had partly controlled (41.7%) or uncontrolled (37.5%) asthma based on the GINA criteria [11]. Thirteen patients (54.2%) exhibited AHR in the methacholine challenge test and 15 (62.5%) showed a BDR, defined as an FEV₁ increase of 200 mL and 12% from baseline after salbutamol inhalation. The baseline percentages of the predicted values of FEV₁, FEV₁/FVC, and FEF_25–75 were 82.5 ± 14.5%, 73.7 ± 9.0% and 64.9 ± 24.2%, respectively. The fractional exhaled nitric oxide (FeNO) values and blood eosinophil counts were 71.7 ± 65.0 ppb and 875.0 ± 356.8/μL, respectively. No significant differences were observed in the baseline characteristics between the treatment groups (Table 1).

Asthma treatment outcomes

Asthma treatment outcomes

During the two 6-week treatment periods, the mean number of inhalations per day was 2.55 ± 1.13, with a mean as-needed usage of 0.55 ± 1.13 inhalations per day. A total of 16 patients (66.7%) used inhalers for maintenance therapy, incorporating as-needed usage. The mean daily inhalations of BDP/F and BUD/F were 2.76 ± 1.29 and 2.44 ± 0.94, respectively, while the mean as-needed inhalations were 0.67 ± 1.29 and 0.44 ± 0.94, respectively. There were no significant differences between the groups in terms of inhalation pattern or usage.

Intervisit differences in lung function and symptom control status

Intervisit differences in lung function and symptom control status

No statistically significant differences in lung function or asthma control were observed between the start and end of each treatment phase in groups A and B. However, ACT scores in group B significantly increased during BDP/F treatment, raising from 18.00 ± 3.88 to 20.42 ± 2.27 (Tables 2, 3).

Comparison of BDP/F and BUD/F in the lung function and symptom control status

Comparison of BDP/F and BUD/F in the lung function and symptom control status

The treatment effects on small airway function, as assessed by FEF_25–75% pred, were similar between the BDP/F and BUD/F (5.79 ± 38.34 vs. −1.36 ± 14.93, p = 0.399) (Fig. 3). Similarly, there were no differences between the BDP/F and BUD/F groups in the average changes from baseline in FEV₁, FVC, and FEV₁/FVC ratios. BDP/F exhibited improvement trends in ACT, ACQ, and QLQAKA scores over the 6-week treatment period; however, these trends were not statistically significant (Supplementary Table 1). Subgroup analyses were conducted based on FeNO levels (≥ 40 ppb, n = 15), blood eosinophil counts (≥ 300/μL, n = 13), positive BDR (n = 15), and a positive methacholine bronchial provocation test (MBPT) (n = 13). The MBPT subgroup revealed significant differences in ACT scores between BDP/F and BUD/F treatments (0.92 ± 2.25 vs. −1.31 ± 3.04, p = 0.044). However, no significant differences were observed in the subgroups based on the BDR, blood eosinophil counts, or FeNO levels (Supplementary Table 2).

AEs

AEs

Two patients (8.3%) reported at least one treatment-emergent AE during the BDP/F treatment. The reported AEs included coughing, sputum production, and palpitations; however, all patients completed the study without discontinuation. No serious AEs or deaths were reported.

DISCUSSION

This crossover study, designed to evaluate the impact of extrafine particle size ICS in patients with moderate asthma, did not demonstrate significant improvements in symptom control, large airway function (measured by FEV₁ and FEV₁/FVC), or small airway function (measured by FEF_25–75% pred) compared to non-extrafine ICS. The ACT scores in group B, treated with BDP/F, showed statistically significant improvements. However, intervisit difference analysis did not account for factors such as individual patient characteristics or order effects. To address these limitations, the mixed-effects model was employed, offering greater robustness and reliability than intervisit difference analysis. These findings, which contrast with our previous study, illustrate that evaluating clinical benefits in inhalation therapy cannot be based solely on particle size, as multiple complex variables influence treatment outcomes [10].

Asthma, previously thought to affect only the large airways, is now recognized as a condition characterized by chronic inflammation throughout the lungs. Inflammation is characterized by mucus plugging, increased T cells, activated eosinophils, and major basic proteins in both the central and small airways [15]. Novel ICS formulations, such as beclomethasone dipropionate and ciclesonide, have been specifically designed to target small airway inflammation [16]. These formulations yield smaller particles, which facilitate better access to the distal airways. Imaging studies have suggested that these formulations produce beneficial changes in the distal airways [17,18].

Smaller particle sizes may confer additional clinical benefits by penetrating smaller airways and enhancing efficacy [19–21]. However, the practical impact of these benefits remains inconclusive, as evidenced by our study and meta-analysis [22]. El Baou et al. [22] conducted a meta-analysis of 23 trials and found no significant differences between standard and small-particle ICS in changes in FEV₁, morning peak expiratory flow (PEF), or FEF_25–75% pred. Additionally, benefit-risk plots across five efficacy endpoints, including FEV₁, morning PEF, FEF_25–75%, asthma symptoms, and rescue medication use, did not reveal clinically meaningful differences.

Although extrafine particles are more effectively distributed in peripheral airways [23], it is commonly believed that particles smaller than 1 μm are largely exhaled due to their extremely low settling velocity, which consequently limits their therapeutic activity within the lungs. The rapid relief of airway constriction achieved with initial ICS treatment may lessen the incremental benefits provided by smaller particles [24].

In studies using the same extrafine ICS, DPIs did not demonstrate significant improvements in small airway obstruction, in contrast to the findings observed with pMDIs [10]. This discrepancy may stem from differences in aerosol generation mechanisms, reliance on patient inhalation efforts for particle delivery efficiency, or variations in the particle deposition patterns between the two devices. Moreover, some patients may struggle to achieve the necessary inspiratory flow for effective DPI use, potentially reducing the therapeutic benefits of extrafine particles in treating small airway obstructions. Collectively, these results suggest that targeted aerosol delivery to the conducting or peripheral airways is not solely dependent on particle size, but is instead determined by a complex interplay of various factors [25–27].

Given the non-significant results across all parameters in this crossover study, subgroup analyses were performed. Notably, BDP/F significantly improved ACT scores in patients positive for MBPT. Mild-to-moderate asthmatic patients with small airway dysfunction (SAD), as assessed by impulse oscillometry (IOS), exhibit excessive bronchoconstriction during methacholine challenge, highlighting the significant role of small airways in bronchial hyperresponsiveness [28]. These findings emphasize the importance of small-particle aerosols in the management of patients with AHR. Additionally, future studies should investigate the impact of extrafine particles in a patient group exhibiting both AHR and reversibility, which are the two key characteristics of airway variability.

Asthma control is significantly influenced by treatment adherence, which is enhanced by combining MART in a single inhaler and by using a device optimized for ease of use [29,30]. Few studies have evaluated the potential correlation between extrafine particles and the benefits of MART in asthma control, lung function, and quality of life [31,32]. In this study, the mean as-needed inhaler usage for symptom relief was aligned with previously published data on MART usage in real-life settings among Korean and European patients, despite thorough education on MART use provided at every visit [14,33]. We observed no statistically significant differences in either group even with the application of MART. These findings underscore the need for further investigation through prospective trials or real-world studies to assess whether extrafine particles enhance MART by uniformly addressing airway inflammation.

Our study has two major strengths. First, it focused on a well-defined population of patients with a clinical need for ICS/LABA and provided evidence supporting the use of MART for moderate asthma. Second, all subjects received fluticasone propionate as a controller medication during the 4-week run-in and washout periods to mitigate the potential carryover effects of ICS/LABA in the crossover design, considering the half-life of ICS medications. Furthermore, a mixed-effects model was employed for statistical analysis to evaluate treatment effects and account for potential carryover effects. However, this study has some limitations. First, the small sample size and short study duration limited the statistical power, although the crossover design partially offsets this limitation. We acknowledge that the small sample size may affect the generalizability of our findings and limit the precision of subgroup analyses. Second, despite education and monitoring of inhaler use, we could not evaluate the impact of factors beyond particle size on asthma control, owing to the lack of robust verification methods. The particle size of the inhaler was not independently measured in this study; instead, the designation of extrafine particles relied entirely on the limited information obtained from radiolabeling studies conducted on a small sample and data provided by the manufacturer [34,35]. Practically, it is challenging to directly measure the particle size in such studies. Third, while FEF_25–75% pred is a commonly used marker of SAD, it may not fully capture the nuanced changes in small airway pathology. Some studies have indicated that even parameters specific to small airways lack validated clinical significance and reliability [36,37]. Postma et al. [38] showed that no single variable defines SAD; however, tools such as IOS, multiple breath nitrogen washouts, lung volumes, and spirometry can contribute. Fourth, we only recruited patients categorized according to GINA step 3. SAD is prevalent across all asthma severities but is particularly significant in severe diseases [38,39]. Future studies should also focus on patients with moderate to severe asthma (GINA step 3–5) to comprehensively evaluate the role of extrafine ICSs. Fifth, it has been reported that the maximal effect of ICS typically requires 3–6 months to manifest [40]. Extending the treatment period beyond six weeks may have provided a more robust evaluation of the impact of ICS particle size, allowing for a more accurate assessment of its effectiveness. Finally, the comparison would have been more accurate if the two inhalers had shared identical components and formulations, differing only in particle size. Such a distinction would enable a more precise evaluation of the impact of the particle size on the performance and efficacy.

In conclusion, our study demonstrated that extrafine ICS treatment did not result in significant improvements in small airway function or overall asthma control compared to non-extrafine ICS treatment in moderate asthma. These results suggest that, while particle size plays a role, other factors, such as patient-specific and inhalation characteristics, may be equally important in determining clinical outcomes. Identifying patient subgroups that could benefit the most from extrafine ICS should be a priority for future research, paving the way for a more personalized approach to asthma management. Moreover, long-term studies incorporating advanced tools to assess small airway function are necessary to explore the enduring effects of extrafine particles on asthma.

KEY MESSAGE

1. Existing studies suggest that while extrafine particles may penetrate the small airways more effectively, their clinical significance remains uncertain owing to mixed evidence.

2. Our study showed that extrafine particle ICS treatment did not result in significant improvements in small airway function or overall asthma control compared to non-extrafine ICS treatment in patients with moderate asthma.

3. These findings highlight that factors beyond particle size, such as patient-specific characteristics and inhalation techniques, are critical for determining treatment outcomes.

4. Further research with larger sample sizes and more advanced tools is needed to evaluate the potential long-term benefits of extrafine particles in asthma management.

Supplementary Information

kjim-2024-393-Supplementary-Table-1.pdf

kjim-2024-393-Supplementary-Table-2.pdf

Notes

CRedit authorship contributions

Sang Pyo Lee: conceptualization, methodology, resources, investigation, formal analysis, validation, writing - review & editing, supervision; Sang Min Lee: conceptualization, methodology, resources, investigation, data curation, formal analysis, validation, software, writing - review & editing, supervision; Sung-Yoon Kang: conceptualization, methodology, resources, investigation, data curation, formal analysis, validation, software, writing - original draft, writing - review & editing, visualization, supervision, project administration, funding acquisition

Conflicts of Interest

Conflicts of interest

The authors disclose no conflicts.

Notes

Funding

This study was supported by the Gachon University Gil Medical Center (FRD 2021-13) and Chung-Ram Research Grant 2024 from the Korean Association of Internal Medicine.

References

REFERENCES

1. Porsbjerg C, Melén E, Lehtimäki L, Shaw D. Asthma. Lancet 2023;401:858–873.
[Article] [PubMed]

2. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003;139(5 Pt 1):359–370.
[Article] [PubMed]

3. Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res 2010;690:24–39.
[Article] [PubMed] [PMC]

4. Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C, P04073 Study Investigators. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J 2012;39:279–289.
[Article] [PubMed]

5. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405–1411.
[Article] [PubMed]

6. Usmani OS, Singh D, Spinola M, Bizzi A, Barnes PJ. The prevalence of small airways disease in adult asthma: a systematic literature review. Respir Med 2016;116:19–27.
[Article] [PubMed]

7. Scichilone N, Contoli M, Paleari D, et al. Assessing and accessing the small airways; implications for asthma management. Pulm Pharmacol Ther 2013;26:172–179.
[Article] [PubMed]

8. Usmani OS. Small airways dysfunction in asthma: evaluation and management to improve asthma control. Allergy Asthma Immunol Res 2014;6:376–388.
[Article] [PubMed] [PMC]

9. Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol 2009;124(6 Suppl):S88–S93.
[Article] [PubMed]

10. Nam TH, Kang SY, Lee SM, Kim TB, Lee SP. Comparison of two pMDIs in adult asthmatics: a randomized double-blind double-dummy clinical trial. Tuberc Respir Dis (Seoul) 2022;85:25–36.
[Article] [PubMed]

11. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2024 [Internet] Fontana (WI): Global Initiative for Asthma, c2024. [cited 2024 Nov 11]. Available from: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf.

12. Kanniess F, Scuri M, Vezzoli S, Francisco C, Petruzzelli S. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler^®) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: a randomised, double-blind trial. Pulm Pharmacol Ther 2015;30:121–127.
[Article] [PubMed]

13. Morice AH, Peterson S, Beckman O, Osmanliev D. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. Int J Clin Pract 2007;61:1874–1883.
[Article] [PubMed]

14. Kim SH, Kim TB, Kim SH, et al. Real-life clinical use of Symbicort ^® maintenance and reliever therapy for asthmatic patients in Korea. Allergy Asthma Immunol Res 2018;10:88–94.
[Article] [PubMed]

15. Carr TF, Altisheh R, Zitt M. Small airways disease and severe asthma. World Allergy Organ J 2017;10:20.
[Article] [PubMed] [PMC]

16. Cohen J, Postma DS, Douma WR, Vonk JM, De Boer AH, ten Hacken NH. Particle size matters: diagnostics and treatment of small airways involvement in asthma. Eur Respir J 2011;37:532–540.
[Article] [PubMed]

17. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006;100:375–384.
[Article] [PubMed]

18. Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 1999;104:S250–S252.
[Article] [PubMed]

19. Benfante A, Basile M, Battaglia S, Spatafora M, Scichilone N. The use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics. Ther Clin Risk Manag 2016;12:1553–1562.
[Article] [PubMed] [PMC]

20. Lavorini F, Pedersen S, Usmani OS, Aerosol Drug Management Improvement Team (ADMIT). Dilemmas, confusion, and misconceptions related to small airways directed therapy. Chest 2017;151:1345–1355.
[Article] [PubMed]

21. Papi A, Mansur AH, Pertseva T, et al. Long-term fluticasone propionate/formoterol fumarate combination therapy is associated with a low incidence of severe asthma exacerbations. J Aerosol Med Pulm Drug Deliv 2016;29:346–361.
[Article] [PubMed] [PMC]

22. El Baou C, Di Santostefano RL, Alfonso-Cristancho R, et al. Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis. BMC Pulm Med 2017;17:31.
[PubMed] [PMC]

23. Nicolini G, Scichilone N, Bizzi A, Papi A, Fabbri LM. Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations. Ther Clin Risk Manag 2008;4:855–864.
[PubMed] [PMC]

24. de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. Can ‘extrafine’ dry powder aerosols improve lung deposition? Eur J Pharm Biopharm 2015;96:143–151.
[Article] [PubMed]

25. Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chrystyn H. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med 2010;104:1237–1245.
[Article] [PubMed]

26. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588–599.
[Article] [PubMed] [PMC]

27. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006;58:996–1008.
[Article] [PubMed]

28. Alfieri V, Aiello M, Pisi R, et al. Small airway dysfunction is associated to excessive bronchoconstriction in asthmatic patients. Respir Res 2014;15:86.
[Article] [PubMed] [PMC]

29. Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone- formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med 2013;1:23–31.
[Article] [PubMed]

30. Rabe KF, Pizzichini E, Ställberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006;129:246–256.
[Article] [PubMed]

31. Braido F, Arnaboldi E, Barile S, et al. BDP/FF NEXThaler to improve asthma control status in the real world: the NEWTON study. J Asthma Allergy 2023;16:1177–1186.
[Article] [PubMed] [PMC]

32. Dębowski T, Marko M, Rogala B, Majak P, Pawliczak R. Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy - CONTROL study. Pulm Pharmacol Ther 2024;84:102272.
[Article] [PubMed]

33. Ställberg B, Naya I, Ekelund J, Eckerwall G. Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy. Int J Clin Pharmacol Ther 2015;53:447–455.
[Article] [PubMed] [PMC]

34. Warren S, Taylor G, Smith J, Buck H, Parry-Billings M. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique. J Aerosol Med 2002;15:15–25.
[Article] [PubMed]

35. Corradi M, Chrystyn H, Cosio BG, et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Expert Opin Drug Deliv 2014;11:1497–1506.
[Article] [PubMed]

36. Quanjer PH, Weiner DJ, Pretto JJ, Brazzale DJ, Boros PW. Measurement of FEF_25–75% and FEF_75% does not contribute to clinical decision making. Eur Respir J 2014;43:1051–1058.
[Article] [PubMed]

37. Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 2008;177:253–260.
[Article] [PubMed]

38. Postma DS, Brightling C, Baldi S, ATLANTIS study group, et al. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med 2019;7:402–416.
[Article] [PubMed]

39. van der Wiel E, ten Hacken NH, Postma DS, van den Berge M. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol 2013;131:646–657.
[Article] [PubMed]

40. Pizzichini E, Brusselle G, Edwards D, et al. Run-in periods and treatment outcomes in asthma trials: a narrative review. Contemp Clin Trials Commun 2024;42:101382.
[Article] [PubMed] [PMC]